McKesson IDs 5 2016 trends for hospital/health system pharmacies
Continued Growth in Specialty Market: The growth in specialty pharmaceuticals spend continues to outpace the growth in the overall pharmaceutical market and is the top spend category for health systems pharmacies. As more biosimilars reach the market, specialty pharmaceuticals will start to face increased competition, which will have a positive impact on pharmacies’ cost reduction efforts. However, health systems treating patients in the ambulatory setting and reimbursed through the average sales price model will see a corresponding drop in revenue. While the growth of limited networks and exclusive distribution channels for many specialty pharmaceuticals challenge health systems’ continuity of care initiatives, opportunities still exist for those that understand and can demonstrate the unique clinical and operational competencies and expertise required for specialty pharmacy;
Health System Pharmacy Seen as a Revenue and Margin Generator: Managing costs will always be important; however, health systems’ leaders are increasingly looking at the pharmacy as more of a revenue and margin generator and less as a cost center. Whether still operating in a fee-for-service environment or shifting to a performance or value-based reimbursement model, the pharmacy can have significant impact on the overall P&L of a health system by focusing on incremental revenue opportunities such as ambulatory, specialty and mail-order pharmacy services. Not only does an integrated pharmacy care model impact the bottom line; the focus on optimal medication therapy management in the ambulatory care setting can help health systems improve continuity of care and medication adherence, and reduce readmissions;
Industry Consolidation Increasing Need for Supply Chain Efficiency: In 2015, there has continued to be significant consolidation among hospitals and health systems, pharmaceutical manufacturers, retail pharmacy chains, and payers. Since nearly half of a hospital’s total operating expenses are for supplies, drugs and consumables, large health systems are looking for better integration and efficiency across the supply chain. An efficient pharmacy supply chain that is scaled properly can help streamline workflow, improve productivity and enable tighter inventory management. With an enterprise-wide analysis of total supply spend and patient utilization and outcomes, health system pharmacies can improve network access, analyze contract performance and improve payer performance;
Increasing Oversight of 340B Program: The Health Resources and Services Administration proposed 340B Omnibus Guidance recently underwent public comment. Also known as the Mega-Guidance, it contains clarifications of existing 340B program elements such as patient definition, covered outpatient drugs and contract pharmacy. There are also several new areas covered including specialty pharmacy and limited distribution arrangements. While the final guidance has not yet been promulgated by HRSA, all health systems — even well-established, successful 340B health systems and pharmacies — should conduct a comprehensive evaluation of their current programs to identify if the guidance will create any gaps in their program and develop action plans to address the potential business impact of these changes; and
- Leveraging Pharmacy Analytics to Make Strategic Business Decisions: Big Data is still a buzzword across healthcare and other industries. Integrating comprehensive pharmacy analytics to track and monitor drug spend and use, patient care, and quality is a top priority for health systems. Organizations can use this information to make better financial, clinical and operational decisions and drive improved outcomes. Lack of connectivity or interoperability of health records between pharmacy and other providers can be a major patient safety issue and continues to plague the industry overall. However, initiatives such as the Commonwell Health Alliance are making progress to make healthcare data available and accessible to providers across care settings.
McKesson to spotlight solutions at ASHP Midyear Clinical Meeting 2015
- McKesson Health Systems: McKesson helps customers improve financial outcomes through its evidence-based programs, products and services including specialty and ambulatory pharmacy consulting, pharmacy revenue cycle analysis and support, and indigent drug recovery solutions. In addition, McKesson’s supply chain management solutions such as its competitive generics portfolio, Lean Six Sigma methodologies and training, timely drug shortage information, specialty inventory management technology, and single-source access to specialty products help customers increase efficiency and deliver measurable, time-saving results. McKesson provides actionable pharmacy insights through detailed drug spend analytics, 340B program management and improved billing accuracy;
- McKesson Pharmacy Systems & Automation: MPS&A offers two new solutions to improve pharmacy outcomes – Adherence Performance Solution and Clinical Programs Solution. The Adherence Performance Solution online dashboard provides valuable data to help health system pharmacies understand and act on patient medication adherence behaviors. The dashboard identifies patients to target for an adherence program based on their current level of adherence and generates data to compare adherence performance to the rest of the market segment to prove the value of the pharmacy to preferred prescriber networks. The Clinical Programs Solution platform integrates with MPS&A’s pharmacy-management system so that health system pharmacies can easily add and manage multiple clinical programs for patients. Whether health system pharmacies use stand-alone vendor services or self-directed programs, the Clinical Programs Solution can save time and money by automatically synchronizing enrolled patient data between clinical programs and the hospital pharmacy’s system, identifying potential vendor programs for patients with specific medical conditions, and giving them easy-to-use tools to build their own customized clinical programs; and
- Parata: McKesson’s automation partner, Parata, will be demonstrating its Parata Max and Parata Mini robotic dispensing technology to show how automation solutions can fill scripts safely; prevent controlled-substance diversion; manage an increasing script volume; and store, monitor and track drugs safely and securely. Parata automation allows health system pharmacists to free up labor for other value-added activities, such as medication reconciliation consulting, patient education, and post-discharge interventions to improve patient outcomes. Parata’s PASS 208 adherence strip packager will also be featured within the McKesson booth to show how health system pharmacists can make it easy for patients to take the right medication at the right time, every time. PASS adherence packaging organizes medications the way patients take them, by day and time of dose, and empowers pharmacists to take a more proactive role in patient outcomes, avoid readmission for discharged patients, support common “med to bed” health system programs, and provide services to other health system entities such as a hospice or care center.
Critical role of treatment support programs in diabetes self-management
With the presidential election in 2016, access to health care and cost of medications are some of the most hotly debated topics in America. Consumers, however, have a limited understanding of health insurance, which studies have shown can lead to suboptimal decisions related to their own health.1
For the 29.1 million Americans living with diabetes,2 navigating this complicated landscape can be a hurdle to successful diabetes management, affecting their likelihood to fill their prescription and take their medicine as prescribed. Data show nonadherence can then lead to lower success rates in reaching treatment targets, increased adverse events for patients, and contribute to the rising costs of diabetes care.3,4
Novo Nordisk, a world leader in diabetes care, is taking a proactive approach to help patients and clinical communities gain access to important medications through its personalized treatment support programs. The company’s health care professional hub, NovoMedLink.com, offers product-support information, educational videos, and access to free educational resources for use in clinical practice.
“Developing personalized tools to assist in treatment access is a primary focus of our patient-support efforts,” said Sean Phillips, Vice President of Managed Markets, Novo Nordisk Inc. “By connecting patients with information and resources related to health care coverage, health care providers and pharmacists play a critical role in helping patients stick to a treatment plan that is achievable for them.”
The site also offers prescription savings details for certain Novo Nordisk diabetes treatments available in the United States, including $20 and $25 co-pay cards and information on receiving a free box of Novo Nordisk needles for eligible patients.
- Loewenstein G, et al. Consumers’ misunderstanding of health insurance. J Health Econ. 2013;32:580-862. http://scholar.harvard.edu/files/laibson/files/consumers_jhe_sept2013.pdf?m=1391524638. Accessed November 4, 2015.
- Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed November 4, 2015.
- Nasseh K, et al. Cost of medication nonadherence associated with diabetes, hypertension, and dyslipidemia. Am J Pharm Benefits. 2012;4(2):e41-e47. http://adhereforhealth.org/wpcontent/uploads/pdf/CostofMedicationNonadherenceAssociatedwithDiabetesHypertensionandDyslipidemia_Nasseh2010.pdf. Accessed November 4, 2015.
- Iuga AO and McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934668/. Accessed November 4, 2015.